---
title: Arm-hand Boost Program During Inpatient Rehabilitation After Stroke
nct_id: NCT04584177
overall_status: COMPLETED
phase: NA
sponsor: Jessa Hospital
study_type: INTERVENTIONAL
primary_condition: Stroke
countries: Belgium
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04584177.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04584177"
ct_last_update_post_date: 2021-02-11
last_seen_at: "2026-05-12T07:14:13.884Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Arm-hand Boost Program During Inpatient Rehabilitation After Stroke

**Official Title:** Arm-hand Boost Program During Inpatient Rehabilitation After Stroke: Pilot Randomized Controlled Trial

**NCT ID:** [NCT04584177](https://clinicaltrials.gov/study/NCT04584177)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Jessa Hospital
- **Conditions:** Stroke
- **Start Date:** 2019-05-09
- **Completion Date:** 2020-11-03
- **CT.gov Last Update:** 2021-02-11

## Brief Summary

A pilot cross-over RCT including participants with sub-acute stroke is conducted in an inpatient rehabilitation setting. The experimental group (EG) receives an arm-hand boost program on top of their usual care program. The control group (CG) receives a dose-matched program of strengthening exercises for the lower limbs and general reconditioning. After 4 weeks, a cross-over is performed. Before, after 4 weeks and after 8 weeks of additional therapy, different clinical outcome measures for the upper limb are administered.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* first stroke, as defined by WHO,
* minimal stay of 4 weeks in inpatient setting at study start
* minimally 18 years old
* being able to sit independently (trunk control test, item 3 = 25),
* motor impairment in the upper limb (Fugl-Meyer assessment, stage 2 (synergies): 8-17p, or stage 2: \<8p combined witht stage 5 (hand): \>6p
* sufficient cooperation to perform intervention and evaluations

Exclusion Criteria:

* musculoskeletal and/or other neurological impairments with permanent damage that may hinder the study
* subdural hematoma, tumor, encephalitis, trauma, or other that lead to similar symptoms as stroke
* severe communication, cognitive or language impairments that hinder the investigations
* no written informed consent
```

## Arms

- **Arm-hand BOOST + Control** (EXPERIMENTAL) — First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
- **Control + Arm-hand BOOST** (EXPERIMENTAL) — First 4 weeks control program, afterwards 4 weeks arm-hand boost program

## Interventions

- **Arm-hand BOOST program** (BEHAVIORAL) — The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
- **Control program** (BEHAVIORAL) — A dose-matched program of strengthening exercises for the lower limbs and general reconditioning

## Primary Outcomes

- **Change from Fugl-Meyer Assessment-Upper Extremity at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_ — UL assessment - Function
- **Change from Fugl-Meyer Assessment-Upper Extremity at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_ — UL assessment - Function
- **Change from Action Research Arm Test at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_ — UL Assessment - Activities
- **Change from Action Research Arm Test at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_ — UL Assessment - Activities

## Secondary Outcomes

- **Change from Jebsen Taylor hand function test at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_
- **Change from Jebsen Taylor hand function test at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_
- **Change from Rivermead Motor Assessment Arm function at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_
- **Change from Rivermead Motor Assessment Arm function at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_
- **Change from Stroke upper limb capacity scale (SULCS) at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_
- **Change from Stroke upper limb capacity scale (SULCS) at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_
- **Change from Box & Block test at 4 weeks** _(time frame: Between baseline and first 4 weeks of study)_
- **Change from Box & Block test at 8 weeks** _(time frame: Between baseline and end of study (=8 weeks))_

## Locations (1)

- Jessa Hospital, Campus Sint-Ursula, Herk-de-Stad, Belgium

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.jessa hospital, campus sint-ursula|herk-de-stad||belgium` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04584177.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04584177*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*